Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660394 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
A Phase 3 study of Dravet Syndrome, sponsored by Longboard Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06660394 is a Phase 3 study of Dravet Syndrome that is actively recruiting participants, run by Longboard Pharmaceuticals. The registered enrollment target is 160 participants, above the 97-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06660394, a Phase 3 study of Dravet Syndrome, is actively recruiting participants, sponsored by Longboard Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LP352
Study Locations (20)
Florida
- NW FL Clinical Research Group, LLC - Gulf Breeze
- Nicklaus Children's Hospital - PIN - Miami
- Research Institute of Orlando LLC - Orlando
- Pediatric Epilepsy and Neurology Specialists - Tampa
California
- David Geffen School of Medicine at UCLA - Los Angeles
- The Stanford Division of Child Neurology - Palo Alto
- UCSF Children's Hospital - San Francisco
New Jersey
- Institute of Neurology and Neurosurgery at Saint Barnabas, LLC - Livingston
- Northeast Regional Epilepsy Group - Morristown - 310 Madison Ave - Morristown
Texas
- Child Neurology Consultants of Austin - 6811 Austin Center Blvd - Austin
- Cook Children's Jane and John Justin Neurosciences Center - PIN - Fort Worth
Arkansas
- Arkansas Children's Hospital - PIN - Little Rock
Colorado
- Children's Hospital Colorado. - Aurora
Georgia
- Rare Disease Research, LLC - Atlanta - RDR - PIN - Atlanta
Illinois
- Ann and Robert H Lurie Childrens Hospital of Chicago - PIN - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2026-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660394
The ClinicalTrials.gov registry entry for NCT06660394 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (65% higher). The listed sponsor is Longboard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06660394 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06660394 about?
NCT06660394 is a clinical study titled "A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)". This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance per...
What is the current status of trial NCT06660394?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2024-09-25. Estimated completion is 2026-10-02.
What conditions does trial NCT06660394 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT06660394?
The interventions under investigation include: Placebo (DRUG), LP352 (DRUG).
Who is sponsoring clinical trial NCT06660394?
This trial is sponsored by Longboard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660394 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
GABA Biomarkers in Dravet Syndrome
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.